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26 Oral PresentationsSCT, respectively. A trend for more severe aGVHD and extensive
cGVHD was observed in patients who received peripheral blood
SC from MSD. One year-treatment-related mortality is still low
(7%) in both groups and reflects the high performance quality of
the participating centers. We conclude that allogeneic SCT from
matched donors identified by high resolution typing provides an ex-
cellent chance to rescue children and adolescents with high risk
ALL. The combination of CSA, short MTX and ATG prevents
acute and chronic GVHD without jeopardising the GVL effect.63
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Background: Bone marrow transplantation benefits patients
with lysosomal and peroxisomal storage diseases (LSD). Umbilical
cord blood (UCB) may be potential graft source for many patients
lacking suitable adult donors. We present the outcomes of Unre-
latedUCB transplantation (UCBT) in a large series of LSDpatients
from a single center. Methods: Using myeloablative conditioning
with busulfan1cyclophosphamide1antithymocyte globulin and
graft-versus-host disease (GvHD) prophylaxis with Cyclospori-
ne1methylprednisolone(n 5 125) or cyclosporine1cellcept (n 5
34), 159 consecutive LSD patients with Hurler, Krabbe, Sanfilippo,
Metachromatic Leukodystrophy, Adrenoleukodystrophy, Hunter,
and other diagnoses received UCBT at Duke in 1995–2007. CBU
from 8 US public banks were screened and those with high-normal
enzyme utilized. Organ function and disease specific studies were
performed pre- and post-UCBT. KM estimates of engraftment,
survival and GvHD probabilities were calculated and multivariate
models were analyzed for a variety of graft and patient factors.
Results: Sixty-two (39%) were girls; 16.3% minorities; 19.5%
CMV seropositive, and 41.5% had a Lansky\ 80%. Age was 1.5
yrs(range 0.05–26.3). Majority of grafts were 5/6(47%) or 4/
6(46%) by intermediate-res HLA-A and -B and high-res HLA-
DRB1. The median(range) cell dose/kg of TNC(pre-cryo),
TNC(infused), CD34(infused) and CFU(post-thaw) was 9.7 
107(2.2–50.4), 7.6  107(1.5–32.4), 2.1  105(0.4–104.8) and 5.7
 104(0.0–105.3), respectively. The cumulative incidence neutro-
phil and platelet engraftment was 87.1% (95%CI 82%-92%) and
71.0% (95%CI 64%-78%) in a median of 22 and 87 days, respec-
tively. The probability of Grade III/IV acute GvHD was
10.3%(95%CI 5%-15%) by day100. Chronic GvHD developed
in 26(13–limited). Overall Survival(OS) at 1, 3, and 5 years was
71.8%(95%CI 65%-79%), 62.7%(95%CI 55%-71%) and
58.2%(95%CI 50%-67%), respectively. In multivariate analysis,
Lansky 80–100(p \ 0.0001), CFU infused .5.7  104/kg (p 5
0.02), and matched ethnicity(p 5 0.05) increased OS. Once en-
grafted, all but 3 maintained chimerism.90% and all but 4 normal-
ized enzymes. In high performance status(Lansky 80–100) patients,
theOS at 1, 3 and 5 yearswas 88.4%, 83.5%, and 79.5%, respectively.
Conclusions: Unrelated Cord blood is an excellent graft source
for treatment of LSD patients, particularly when transplantation is
performed in early stages. Pre-transplant performance status and
post-thaw CFU dosing were highly predictive of overall survival.64
LUNG BIOPSY (BX) HAS A SIGNIFICANTLY HIGHER DIAGNOSTIC YIELD
COMPARED TO BRONCHOALVEOLAR LAVAGE (BAL) IN PEDIATRIC HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS
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Pulmonary complications (PC) following HSCT remain a signif-
icant source of morbidity and mortality in both the early and late
HSCT period. BAL has been a useful initial diagnostic tool in the
evaluation of post HSCT PC; however, the sensitivity of BAL ver-
sus Lung Bx in pediatric HSCT pts has not been analyzed. We re-
viewed 208 pediatric HSCT recipients who underwent a total of
252 HSCT. Allo (174) Myeloablative Conditioning (MAC)
(54%), Reduced Intensity Conditioning (RIC) (45%)and Auto
(78) All MAC. Sixty-six patients (32%) underwent 107 BAL for fe-
ver, respiratory distress, and/or pulmonary infiltrate(s) on chest X-
ray/CT scan: M:F 5 38:28, median age 10 yrs (.33–21), mean # of
BAL/pt 2 (1–8). The probability of requiring BAL after HSCT in
all pts was 23.7% (CI95:18–29.4); RIC 21% (11.5–30.6) vs MAC
24% (16.8–31.6) p 5 0.61 (NS). The median day s/p Auto and
Allo at the time of BAL was Day 131 and 194, respectively. The
probability of AGVHD Grade II-IV at the time of BAL after Allo
SCT was 70% (50–90) and cGVHD was 85% (57–100). The risk
of having cGVHD was significantly higher in the BAL vs no BAL
group (p\0.001). Pathogenswere identified in 37 BAL (35%): Bac-
teria (16), Fungus (12), Viral (13). Seventeen of the 208 pts (8%) un-
derwent a total of 21 lung biopsies. Nineteen (90%) of the biopsies
identified at least one etiology: Infection (12), Fibrosis (4), GVHD
(5), recurrent malignant disease (1). Of the 9 biopsies that were per-
formed within 30 days of an inconclusive BAL (median 13 days s/p
BAL), 6 (67%) identified at least one infection pathogen: Aspergil-
lus (1), CMV (1), Parainfluenza/Influenza (1), Parainfluenza 3 (1),
MAC (1), HSV-1 (1). There were no Grade III/IV toxicity second-
ary to BAL or Bx. Lung autopsies were performed in thirteen pts
(20%) whom underwent a negative BAL. Five (38%) provided at
least one pathogen previously unidentified via BAL performed
within 30 days: Staph Epi (1), Adenovirus (2), CMV (2), Candida
Glabrata (1). The overall survival (OS) in pts whom required BAL
and lung Bx was 45% (16–75) vs 76% (69–83%, p\ 0.003) in the
no BAL and no Bx group This data suggest that a BAL post
HSCT in pediatric recipients will likely only yield a Diagnosis
(Dx) 35% of the time compared to lung Bx which had a 90% diag-
nostic yield. In the future a paradigm will be required to determine
which pediatric HSCT recipients may benefit by having an initial
lung Bx and foregoing an initial BAL to Dx PC.65
INCIDENCE, PREDISPOSING FACTORS AND OUTCOME OF ENGRAFT-
MENT SYNDROME IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT
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Background: Engraftment syndrome (ES) has been recognized
as an inflammatory condition during neutrophil recovery after he-
matopoietic stem cell transplantation (HSCT) characterized by
non-infectious fever and skin rash. It has been reported to occur fre-
quently after autologous HSCT in children and adults and has been
shown to be an independent risk factor for increased transplant re-
lated mortality. However virtually no data exist on its occurrence
after allogeneic HSCT in children. Methods: To determine inci-
dence, predisposing factors for and complications of ES in a pediat-
ric transplant cohort, we analyzed 61 consecutive recipients of
a myeloablative allogeneic HSCT for the occurrence of ES. Diag-
nosis of ES was established when children presented with $2 of
the following symptoms within 7 days before engraftment: (1) fever
of unknown origin.38.0C, (2) erythematous skin rash, (3) weight
gain $5% and albumin drop # 90% of pretransplant levels or (4)
dyspnea, hypoxia or pulmonary infiltrates. Results: Incidence of
ES in this cohort was 48% (29/61). Post transplant G-CSF admin-
istration (p5 0.03) and a higher number of total nucleated cells (p5
0.02) were significant risk factors predisposing for the development
of ES. Other previously reported factors such as source of stem cells
(BM vs. PB; p5 0.88), underlying disease (malignant vs. non malig-
nant; p 5 0.18), early neutrophil recovery (p 5 0.16) and
